1510837-67-8
Chemical Structure
Sudemycin D6
- CAS No.: 1510837-67-8
- Formula:C27H42N2O5
- Molecular Weight:474.63
IUPAC Name: (S,Z)-5-(((1R,4R)-4-((2E,4E)-5-((3R,5S)-7,7-dimethyl-1,6-dioxaspiro[2.5]octan-5-yl)-3-methylpenta-2,4-dien-1-yl)cyclohexyl)amino)-5-oxopent-3-en-2-yl methylcarbamate
InChIKey: VTGAROJAXFMCLD-IYPHXZOMSA-N
SMILES: CNC(O[C@@H](C)/C=C\C(N[C@@H](CC1)CC[C@@H]1C/C=C(C)/C=C/[C@@H]2C[C@@]3(CC(C)(O2)C)CO3)=O)=O
Biological Activity: Sudemycin D6 is a pre-mRNA splicing modulator with potent antitumour activity. Sudemycin D6 changes splice site usage of the DUSP11 and SRRM1 pre-mRNA. Sudemycin D6 reduces survival and alters cell cycle in haematopoietic cells expressing mutant U2AF1. Sudemycin D6 attenuates mutant U2AF1-induced haematopoietic progenitor cell expansion in U2AF1(S34F) transgenic mice. Sudemycin D6 can be used for cancer research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sudemycin D6 | Sudemycin D6 is a pre-mRNA splicing modulator with potent antitumour activity. Sudemycin D6 changes splice site usage of the DUSP11 and SRRM1 pre-mRNA. Sudemycin D6 reduces survival and alters cell cycle in haematopoietic cells expressing mutant U2AF1. Sudemycin D6 attenuates mutant U2AF1-induced haematopoietic progenitor cell expansion in U2AF1(S34F) transgenic mice. Sudemycin D6 can be used for cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Shirai CL, et al. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun. 2017 Jan 9;8:14060. [Content Brief]
- [2]. Thurman M, et al. Changes in Alternative Splicing as Pharmacodynamic Markers for Sudemycin D6. Biomark Insights. 2017 Sep 12;12:1177271917730557. [Content Brief]
Keywords
